1. 414PDPhase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. (23rd October 2018) Authors: Cho, B C; Perets, R; Bar, J; Ahn, M-J; Kim, D-W; Yoh, K; Nagrial, A; Spigel, D R; Lee, D H; Gutierrez, M; Kotasek, D; Siddiqi, S; Chain, A; Butts, B D; Zhang, Y; Li, X; Cyrus, J; Tse, A; Altura, R A; Rasco, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia. Issue 8 (August 1994) Authors: Peckham, D; Crouch, S; Humphreys, H; Lobo, B; Tse, A; Knox, A J Journal: Thorax Issue: Volume 49:Issue 8(1994) Page Start: 803 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). (8th October 2018) Authors: Marabelle, A; Andtbacka, R; Harrington, K; Melero, I; Leidner, R; de Baere, T; Robert, C; Ascierto, P A; Baurain, J -F; Imperiale, M; Rahimian, S; Tersago, D; Klumper, E; Hendriks, M; Kumar, R; Stern, M; Öhrling, K; Massacesi, C; Tchakov, I; Tse, A Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗